Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03916042 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 206
- Enrollment target
NCT03916042 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 206 participants.
The verdict
NCT03916042, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 206 participants
- Enrollment target
Study Summary
A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects with Dry Eye Disease
Interventions
- DRUG Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID
- DRUG Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2019-11-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03916042
The ClinicalTrials.gov registry entry for NCT03916042 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID is the first listed.
NCT03916042 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03916042 about?
NCT03916042 is a clinical study titled "A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease". A Multi-Center, Phase 2, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% Novel Formulation) Compared to Vehicle in Subjects with Dry Eye Disease
What is the current status of trial NCT03916042?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 206 participants. The study started on 2019-04-23. Estimated completion is 2019-11-22.
What interventions are being tested in trial NCT03916042?
The interventions under investigation include: Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID (DRUG), Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID (DRUG).
Who is sponsoring clinical trial NCT03916042?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.